<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">The PACER trial is a randomised controlled, non-inferiority trial on prophylactic platelet transfusion prior to CVC placement in patients with severe thrombocytopenia. It is an investigator-initiated, multicentre, parallel, randomised controlled, two-arm trial in haematologic and/or intensive care patients with thrombocytopenia and an indication for CVC placement. The PACER trial will be conducted according to the principles of the Declaration of Helsinki as stated in the current version of Fortaleza, Brazil, 2013 [
 <xref ref-type="bibr" rid="CR34">34</xref>] and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Institutional Review Board of the Academic Medical Centre, Amsterdam, the Netherlands, approved the trial protocol under reference number 2015_27#B201662. The trial is registered at 
 <ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5653" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5653</ext-link> (NTR5653). Intensive care patients will be provisionally included under a strategy of deferred consent, which is explained in detail in the ‘Consent’ section below. For patients at the Department of Haematology, written informed consent is obtained prior to randomisation. We adhered to the SPIRIT statement (Additional file 
 <xref rid="MOESM2" ref-type="media">2</xref> SPIRIT checklist).
</p>
